A huge THANK YOU for all your submissions to #iHFCourse! 🙌 📅 Acceptance notifications: 18 Dec 2025 See you in Madrid on 20–21 March 2026!

Join @GMCRosano for #iHFCourse! Learn how to: 🟡 Detect disproportionate LVH early 🟡 Understand #TAVI outcomes in #amyloidosis 🟡 Optimise post-TAVI therapy 📅 20 March • 14:55–15:55 🔗 https://t.co/bEPvii8lRw

⏳ Final hours! Your last chance to submit to #iHFCourse 2026 is here. Don’t let your best HF case sit on your desktop. Send it before midnight! https://t.co/SAfs3EIsSS

Sequencing Quadruple Therapy for HFrEF: Does It Really Matter? 👉always RASI-▶️beta blockers-▶️MRA ▶️SGLT2i? It’s only a mirror the order in which they were historically developed 👉Flexible GDMT sequencing should be permitted in special 👥, such as patients 🎯low blood

🔍 Poor adherence to GDMT remains a major barrier to improving outcomes in heart failure. A new HFA/ESC scientific statement provides insights and solutions. https://t.co/vABmIkaxKo @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd #EJHF

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: Conclusions = Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced

🔥 🗞️ Pharmacological treatment for patients with #obesity & #HF: Focus on #GLP1_RA #EJHF expert consensus document GLP-1 RAs & GIP/GLP-1 RA : #Semaglutide & #Tirzepatide ✅ Evidence of benefits in #HF 💊 Potential synergy with other #HF drugs 🧂 Dosing, tolerability and

Join @EmanueleBarba13 for #iHFCourse! Learn how to: 🟡 Optimise GDMT in HFrEF + sMR 🟡 Read key haemodynamic signatures 🟡 Use percutaneous MR to enable GDMT 📅 20 March • 16:15–17:15 🔗 https://t.co/ugbshZveWy

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document Glucagon-like peptide-1 receptor agonists have emerged as a promising therapeutic option for

New online! Redefining heart failure subtypes according to skeletal muscle mass https://t.co/zHXNpxpgDW

New results from #AHA 2025👇 A polypill combining metoprolol + spironolactone + empagliflozin improved cardiac function and symptoms in HFrEF — more effective than taking the drugs separately. A promising simplified approach. 🔗 Link: https://t.co/P9yBInQpTx

New Phase III data from #AHA shows promising results for zalunfiban. Given at first medical contact in suspected STEMI, it improved early artery patency and reduced 30-day CV events. A potential step forward for prehospital management. 🔗 https://t.co/f8baoX4kQs

🎉 Earn 12 EBAC® CME Credits™ at #iHFCourse 2026! Join the first multidisciplinary heart failure course and boost your skills with valuable CME Credits™. https://t.co/gA0JMSJU6J

🔥 Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the #HFA of the @escardio & the ESC Working Group on Cardiovascular Pharmacotherapy 🔑 Key strategies to improve adherence : 👨🏻‍⚕️ 🩺 For Clinicians 🏥 🚑 For healthcare systems 🧍‍♂️

New HFrEF Many clinicians start 2 components of quadruple GDMT and wait to see how the patient responds If the patient has a HF 🏨 or CV ☠️ prior to Q-GDMT, what should this be attributed to? A. Unexpected rare event B. Natural Hx of HF C. Medical errors of omission

🔔 Part 2 of our latest clinical case is out! How the team managed a patient with severe dilated cardiomyopathy and persistent HF symptoms after 8 weeks of GDMT👉 https://t.co/btX8FeFFzB Plus: @Jolie_Bruno_'s insights on GDMT and reverse remodelling in HFrEF + LBBB.

📽️@IzaUchmanowicz joined the nurses and allied professionals sessions at PCR London Valves this week, sharing how trans-disciplinary collaboration can really support patients undergoing TEER procedures. #PCRLV See you in 2026 at the #iHFCourse for more inspiring exchanges!

🎥 Join @joselmerino for #iHFCourse! Learn how: 🟡Select the right patients for physiological pacing or CRT 🟡Understand the role of PVCs in heart failure 🟡Optimize treatment for atrial fibrillation and HFpEF 🔗 Learn more https://t.co/sPantBLdtf

Good news from Madrid! 🎉 The deadline to submit your clinical case or research for #iHFCourse has been extended to December 7 — and this time, it’s the final extension! 🫣 https://t.co/HYcAou0R9X

👀Seen at PCR London Valves 2025: Our joint session on managing secondary MR — from GDMT to TEER — with the PCR Mitral Focus Group. #PCLV @PCRonline @MariannaAdamo1 @FH_Verbrugge